On April 1st , 2021, Servier announced the successful acquisition of Agios Pharmaceuticals’ commercial, clinical, and research-stage oncology portfolio. This acquisition immediately strengthens Servier’s commercial presence in the U.S. malignant hematology market and provides the potential for long-term growth into the solid tumor space.
As part of the transaction, U.S.-based Agios employees who primarily support the oncology business will join Servier Pharmaceuticals LLC, a U.S. subsidiary of Servier.
“We are pleased to welcome an exceptionally talented team that will allow us to strengthen our strategic focus in oncology and expand our scientific capabilities in cellular metabolism,” said Olivier Laureau, President of Servier. “It is an important milestone in Servier’s oncology strategy as it significantly reinforces the Group’s presence in the U.S. Together, with this expanded team, we remain committed to addressing the unmet needs of patients living with cancer across the globe.”
Did you know?
Servier allocates 50% of its global R&D budget to oncology.
The transaction includes the transfer to Servier of Agios Pharmaceuticals’ oncology assets including a marketed oncology precision medicine in malignant hematology, its clinical oncology pipeline with multiple Phase 3 trials and early-stage assets.
In line with Servier’s strategic ambition to become a renowned player in oncology, this transaction supports the Group’s commitment to provide innovative treatments to cancer patients with unmet medical needs.